Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer.

ABSTRACT:

Purpose

This study aimed to evaluate the feasibility and tolerability of biweekly docetaxel with capecitabine as first-line treatment in advanced gastro-oesophageal cancer.

Methods

Fifty-three patients at median age of 61 years with advanced gastric cancer were included in this prospective, non-randomized, multicentre phase II trial to receive intravenous docetaxel 50 mg/m² on days 1 and 15, and oral capecitabine 1250 mg/m² every 12 h, on days 1-7 and 15-21 of each 28-day cycle. QOL was assessed using EORTC QLQ-C30, together with the gastric module (QLQ-STO 22).

Results

Forty-six patients were evaluable for QOL analyses. No deterioration in global health status was found. Social functioning scores improved, and eating difficulties and pain were a

SUBMITTER: Korkeila EA 

PROVIDER: S-EPMC5527066 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature